Trial Search Results
An Observational Study of Fungal Biomarkers (MK-0000-089)
The purpose of this study is to evaluate the relationship between fungal biomarker levels during anti-fungal therapy and the success of treatment for fungal infection. The primary hypothesis is that over the initial two weeks of anti-fungal therapy, fungal biomarkers from participants with invasive aspergillosis (IA) will be lower for those with a successful clinical outcome compared to those with a failed clinical outcome.
Stanford is currently not accepting patients for this trial.
Merck Sharp & Dohme Corp.
- Other: No Intervention
- Is 16 years of age or older
- Female is either post-menopausal, surgically sterilized, willing to use 2 adequate
methods of birth control, or agrees to abstain from heterosexual activity throughout
- Female of child bearing potential must have a negative pregnancy test
- Male is surgically sterilized, agrees to use an adequate method of contraception, or
agrees to abstain from heterosexual activity for the duration of the study
- Has possible, probable, or confirmed invasive aspergillosis (IA)
- Has had a computed tomography (CT) or magnetic resonance imaging (MRI) scan 72 hours
prior to initiation of anti-fungal therapy
- Has had hemodialysis using cellulose membrane within 2 weeks of study start
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study